Pepsinogen I

There are 13 papers on pepsinogen I in aging research: 1 trial and 9 observational studies in people, 1 in animals, 2 reviews.

Biomarker

13 papers study it9 more mention it6 findings

See all 22 papers on pepsinogen I

“serum levels of PG-I and the PG-I/-II ratio were significantly lower in the CAG group.”
Serology and magnetically controlled capsule gastroscopy for opportunistic screening of high-risk events in gastric cancer development: a cross-sectional studyFrontiers in medicine2026doi:10.3389/fmed.2026.1874613
  • Human trial1
  • Humans9
  • Animals1

Interventions

1

Netazepide

downin humans1−15%

1 study
  1. Netazepide decreases pepsinogen I in humans (-15%).

    “Gastrin increased by 90% in response to GRA as early as 7 d (p-value for treatment.0008), and group I pepsinogens decreased by 15% as early as 7 d (p-value for treatment.0002).”

    Human trial90 dfemalesn = 99

    Randomized controlled trial of an oral gastrin receptor antagonist for the treatment of postmenopausal osteoporosis

    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

  2. Netazepide decreases pepsinogen I in humans (-15% (p = .0002)).

    “group I pepsinogens decreased by 15% as early as 7 d (p-value: .0002)”

    Human trial100 mg daily90 dfemalesn = 99

    Randomized controlled trial of an oral gastrin receptor antagonist for the treatment of postmenopausal osteoporosis

    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

More on Netazepide

Associations

4

Atrophic gastritis

downin humans1

1 study
  1. Atrophic gastritis is associated with pepsinogen I in MCCG-detected CAG.

    “serum levels of PG-I and the PG-I/-II ratio were significantly lower in the CAG group.”

    Humansin MCCG-detected CAG

    Serology and magnetically controlled capsule gastroscopy for opportunistic screening of high-risk events in gastric cancer development: a cross-sectional study

    Frontiers in medicine

More on Atrophic gastritis

Gastric precancerous lesions

downin humans1

1 study
  1. Pepsinogen I is linked with a lower risk of gastric precancerous lesions in H. pylori-positive outpatients.

    “whereas higher PG I, higher PGR, and frequent whole-grain intake were protective.”

    Humansin H. pylori-positive outpatientsn = 82

    Development and internal validation of a risk prediction model for gastric precancerous lesions integrating Helicobacter pylori serologic typing and host susceptibility polymorphisms

    Medicine

More on Gastric precancerous lesions

Age

upin humans1

1 study
  1. Age is associated with pepsinogen I in humans (healthy individuals in northern China) (25.16% increase; median 39.75 to 49.75 μg/L from age 20 to 60 years, then plateau through age 80 years).

    “PG I increased from a median of 39.75 μg/L at age 20 years to 49.75 μg/L at age 60 years, a 25.16% increase”

    Humanshealthy individuals in northern Chinaserumn = 708

    Age- and gender-specific dynamics and next-generation reference intervals for pepsinogen in northern China

    World journal of gastroenterology

Hp-IgG

upin humans1

1 study
  1. Hp-IgG is associated with pepsinogen I in humans (P < 0.001).

    “Hp-IgG level positively correlated with PGI, PGII and G-17 (P < 0.001, P < 0.001, P = 0.006)”

    Humansn = 395

    Changes with aging in gastric biomarkers levels and in biochemical factors associated with Helicobacter pylori infection in asymptomatic Chinese population

    World journal of gastroenterology

More on Hp-IgG

Latest

Dec 2025: 0Jan 2026: 2Feb 2026: 2Mar 2026: 2Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 1Aug 2026: 2Sep 2026: 3Oct 2026: 0Nov 2026: 012 papers in 12 months

See all 22 papers on pepsinogen I